

## **Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030**

Market Report | 2025-10-14 | 377 pages | MarketsandMarkets

### **AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

### **Report description:**

The molecular cytogenetics market is expected to reach USD 1.43 billion in 2030 from USD 1.02 billion in 2025, at a CAGR of 7.1% during the forecast period. The market is driven by a rising prevalence of cancer and genetic disorders, mainly among older adults. The growing application of molecular cytogenetic tests for accurate diagnosis and disease management also plays a crucial role. Furthermore, the emergence of targeted therapies and their integration into personalized medicine are further driving market growth. Nonetheless, the high expenses associated with advanced molecular cytogenetic techniques and the requirement for skilled professionals continue to be major barriers to market expansion.

<https://mnimg.marketsandmarkets.com/Images/molecular-cytogenetic-market-newone-overview.webp>

"Testing kits segment is expected to grow at the highest CAGR during the forecast period"

The testing kits segment is growing at the highest CAGR in the molecular cytogenetics market due to its ease of use, reproducibility, and ability to deliver rapid, accurate results. These kits, including CGH arrays and FISH probe panels, enable standardized detection of chromosomal abnormalities and genetic variations across clinical and research laboratories. By leveraging pre-validated assays and integrated analysis tools, testing kits offer reliable, high-throughput solutions that support oncology, prenatal testing, and genetic disorder diagnostics. Their convenience, accuracy, and scalability make them essential for efficient cytogenetic testing, driving their strong adoption in the market.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

"Cancer application segment holds the largest share of the market"

The cancer applications segment accounts for the largest share of the molecular cytogenetics market. This growth is primarily driven by the rising incidence of cancer worldwide, particularly among the aging population, which is more susceptible to malignancies. Genetic changes and chromosomal abnormalities are major contributors to tumor development, increasing the demand for molecular cytogenetic testing in oncology. Techniques such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) enable the precise detection of these abnormalities, facilitating accurate diagnosis, classification of tumor types, and monitoring of disease progression. Furthermore, increasing investments in cancer research, improvements in healthcare infrastructure, and growing awareness of the benefits of early detection and genetic profiling are contributing to the robust growth of this segment across clinical and research settings globally.

"US is expected to grow at the highest CAGR during the forecast period"

The US is experiencing the highest growth rate in the molecular cytogenetics market due to several factors. The presence of leading cytogenetics companies, advanced research infrastructure, and a large patient base are major drivers of market growth in the country. Additionally, rising adoption of molecular cytogenetic testing in oncology, prenatal screening, and genetic disorder diagnostics is fueling demand. Supportive healthcare regulations, increased funding for genomic research, and the growing focus on precision medicine further contribute to the expansion of the molecular cytogenetics market in the US.

Additionally, the widespread adoption of molecular cytogenetic techniques, such as FISH and CGH, for the accurate detection of chromosomal abnormalities has further supported the growth of molecular cytogenetics. Extensive government and private funding for biomedical research and oncology accelerates innovation and the deployment of cutting-edge testing platforms. The region's stringent regulatory framework ensures product quality and reliability, further strengthening trust in molecular cytogenetic solutions and solidifying North America's dominant position globally.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Tier 1 - 25%, Tier 2 - 35%, and Tier 3 - 40%
- By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
- By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, the Middle East - 10%, and Africa - 5%

F. Hoffmann-La Roche Ltd. (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Revvity (US), PacBio (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), GeneDx, LLC (US), Insight Molecular Diagnostics Inc. (US), BioView (Israel), Oxford Gene Technology IP Limited (UK), Applied Spectral Imaging, Inc. (US), CytoTest Inc. (US), KROMATID (US), Genial Genetic Solutions Ltd. (UK), Cytognomix Inc. (Canada), MetaSystems (Germany), SciGene Corporation (US), Biomodal (UK), Biocare Medical, LLC (US), BioDot (US), and OncoDNA (Belgium) are some of the key companies offering molecular cytogenetics products.

#### Research Coverage

This research report categorizes the molecular cytogenetics market by product & service (kits & reagents [testing kits, probes, fluorescent affinity reagents, other kits & reagents], instruments, consumables, software & services), technique (comparative genomic hybridization [array-based comparative genomic hybridization, standard comparative genomic hybridization], fluorescence in-situ hybridization, chromogenic in-situ hybridization, other techniques), application (cancer, genetic disorders, personalized medicine and other applications), end user (clinical & research laboratories, academic & research institutes, pharmaceutical & biotechnology companies, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the molecular cytogenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the molecular cytogenetics market. This report also includes a competitive analysis of emerging startups in the molecular cytogenetics industry ecosystem.

#### Key Benefits of Buying the Report

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

- Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, and increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments and unfavourable reimbursement scenario), opportunities (untapped emerging markets), and challenges (transition from FISH to array-based techniques) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the molecular cytogenetics market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), among others offering products and services for molecular cytogenetics market. Other companies include Applied Spectral Imaging Inc. (US), Biomodal (UK), Biocare Medical, LLC (US), OncoDNA (Belgium), among others, for the molecular cytogenetics market

## **Table of Contents:**

1 INTRODUCTION	34
1.1 STUDY OBJECTIVES	34
1.2 MARKET DEFINITION	34
1.3 STUDY SCOPE	35
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE	35
1.3.2 INCLUSIONS & EXCLUSIONS	36
1.3.3 YEARS CONSIDERED	36
1.3.4 CURRENCY CONSIDERED	36
1.4 STAKEHOLDERS	37
1.5 SUMMARY OF CHANGES	37
2 RESEARCH METHODOLOGY	38
2.1 RESEARCH DATA	38
2.1.1 SECONDARY DATA	39
2.1.1.1 Key sources of secondary data	39
2.1.1.2 Key objectives of secondary research	39
2.1.2 PRIMARY DATA	40
2.1.2.1 Breakdown of primaries	40
2.1.2.2 Key objectives of primary research	40
2.2 MARKET SIZE ESTIMATION	41
2.2.1 GLOBAL MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION, 2024	41
2.2.1.1 Revenue share analysis (bottom-up approach)	41
2.2.1.2 Secondary data & primary interviews	43
2.2.1.2.1 Insights of primary experts	44
2.2.1.3 MnM repository analysis	44
2.2.2 SEGMENTAL MARKET ASSESSMENT: TOP-DOWN APPROACH	45

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

2.3 MARKET GROWTH RATE PROJECTION	46
2.4 DATA TRIANGULATION	48
2.5 STUDY ASSUMPTIONS	49
2.6 RESEARCH LIMITATIONS	50
2.7 RISK ANALYSIS	50
3 EXECUTIVE SUMMARY	51
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS	51
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS	55
3.3 DISRUPTIVE TRENDS SHAPING MOLECULAR CYTOGENETICS MARKET	56
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS	56
3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST	57
4 PREMIUM INSIGHTS	58
4.1 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION AND COUNTRY	58
4.2 MOLECULAR CYTOGENETICS MARKET SHARE, BY END USER, 2024	59
4.3 MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES	60
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS	62
4.6 VC/PRIVATE EQUITY INVESTMENT TRENDS	62
5 MARKET OVERVIEW	64
5.1 INTRODUCTION	64
5.2 MARKET DYNAMICS	64
5.2.1 DRIVERS	65
5.2.1.1 Advancement and adoption of high-resolution techniques	65
5.2.1.2 Growing focus on targeted cancer treatment	66
5.2.1.3 Increasing penetration of molecular cytogenetics in clinical pathological testing	67
5.2.2 RESTRAINTS	68
5.2.2.1 High cost of advanced instruments	68
5.2.2.2 Unfavorable reimbursement scenario for advanced diagnostic tests	68
5.2.3 OPPORTUNITIES	69
5.2.3.1 Untapped emerging markets	69
5.2.4 CHALLENGES	69
5.2.4.1 Transition from FISH to array-based molecular cytogenetic techniques in diagnostic and research communities	69
5.3 UNMET NEEDS & WHITE SPACES	70
6 INDUSTRY TRENDS	71
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS	71
6.2 CASE STUDY ANALYSIS	71
6.2.1 MOSAIC TETRASOMY 9P TO BE DETECTED BY CNV-SEQ IN PRENATAL DIAGNOSIS	71
6.2.2 PRENATAL DETECTION OF 15Q21.3 AND 16P11.2 MICRODUPLICATION SYNDROMES USING CNV-SEQ AND WES	72
6.2.3 INTEGRATED CNV-SEQ AND KARYOTYPING IN LARGE PRENATAL COHORT FOR CHROMOSOMAL ABNORMALITY DETECTION	72
6.3 TECHNOLOGY ANALYSIS	72
6.3.1 KEY TECHNOLOGIES	73
6.3.1.1 Optical genome mapping	73
6.3.1.2 Next-generation sequencing	73
6.3.2 COMPLEMENTARY TECHNOLOGIES	73
6.3.2.1 CRISPR-based editing	73
?	
6.4 PRICING ANALYSIS	74

6.4.1 AVERAGE SELLING PRICE TREND OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER, 2022-2024	74
6.4.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022-2024	76
6.5 PATENT ANALYSIS	79
6.5.1 METHODOLOGY	79
6.5.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE	79
6.5.3 LIST OF KEY PATENTS	81
6.6 TRADE ANALYSIS	82
6.6.1 IMPORT DATA FOR HS CODE 3822.00, 2020-2024	82
6.6.2 EXPORT DATA FOR HS CODE 3822.00, 2020-2024	83
6.7 VALUE CHAIN ANALYSIS	84
6.8 ECOSYSTEM ANALYSIS	85
6.8.1 ROLE IN ECOSYSTEM	88
6.8.2 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS	88
6.9 PORTER'S FIVE FORCES ANALYSIS	89
6.9.1 INTENSITY OF COMPETITIVE RIVALRY	90
6.9.2 BARGAINING POWER OF SUPPLIERS	91
6.9.3 BARGAINING POWER OF BUYERS	91
6.9.4 THREAT OF SUBSTITUTES	91
6.9.5 THREAT OF NEW ENTRANTS	91
6.10 KEY STAKEHOLDERS & BUYING CRITERIA	92
6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS	92
6.10.2 KEY BUYING CRITERIA	93
6.11 TARIFF & REGULATORY ANALYSIS	94
6.11.1 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00	94
6.11.1.1 US	94
6.11.1.2 European Union	94
6.11.1.3 Asia Pacific	94
6.11.2 REGULATORY LANDSCAPE	95
6.11.2.1 North America	95
6.11.2.1.1 US	95
6.11.2.1.2 Canada	97
6.11.2.2 Europe	97
6.11.2.3 Asia Pacific	99
6.11.2.3.1 Japan	99
6.11.2.3.2 China	100
6.11.2.3.3 India	100
6.11.2.4 Latin America	101
6.11.2.4.1 Brazil	101
?	
6.11.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	102
6.11.4 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES	104
6.12 KEY CONFERENCES & EVENTS, 2025-2026	105
6.13 INVESTMENT & FUNDING SCENARIO	106
6.14 IMPACT OF AI/GEN AI ON MOLECULAR CYTOGENETICS MARKET	107
6.15 IMPACT OF 2025 US TARIFF ON MOLECULAR CYTOGENETICS MARKET	109
6.15.1 INTRODUCTION	109
6.15.2 KEY TARIFF RATES	109

6.15.3 PRICE IMPACT ANALYSIS	111
6.15.4 KEY IMPACT ON COUNTRIES/REGIONS	112
6.15.4.1 North America	112
6.15.4.1.1 US	112
6.15.4.2 Europe	113
6.15.4.3 Asia Pacific	113
6.15.5 IMPACT OF END-USE INDUSTRIES	114
6.15.5.1 Clinical & diagnostic laboratories	114
6.15.5.2 Academic & research institutes	114
6.15.5.3 Pharmaceutical & biotechnology companies	114
7 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE	115
7.1 INTRODUCTION	116
7.2 KITS & REAGENTS	116
7.2.1 TESTING KITS	120
7.2.1.1 Standardized and integrated kit workflows to propel market growth	120
7.2.2 PROBES	124
7.2.2.1 Advances in oligonucleotide probe chemistry, multiplexing, and regulatory-driven product modernization to boost market	124
7.2.3 FLUORESCENT AFFINITY REAGENTS	127
7.2.3.1 Improved fluorochrome chemistry and pre-validated conjugates paired with advanced spectral imaging to drive growth	127
7.2.4 OTHER KITS & REAGENTS	131
7.3 CONSUMABLES	134
7.3.1 STANDARDIZATION AND EXPANDING CLINICAL APPLICATIONS TO PROMOTE MARKET GROWTH	134
7.4 INSTRUMENTS	138
7.4.1 AUTOMATION, AI-ENABLED IMAGING, AND INTEGRATED PLATFORMS TO DRIVE MARKET	138
7.5 SOFTWARE & SERVICES	141
7.5.1 AI INTEGRATION, WORKFLOW STANDARDIZATION, AND CLOUD-ENABLED DATA MANAGEMENT TO DRIVE MARKET	141
?	
8 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE	145
8.1 INTRODUCTION	146
8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)	146
8.2.1 INTEGRATION OF FISH AND ADVANCED IMAGING TECHNOLOGIES TO DRIVE GROWTH	146
8.3 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH)	150
8.3.1 BETTER CLINICAL ACCEPTANCE AND IMPROVED TECHNOLOGICAL INTEGRATION TO PROPEL MARKET GROWTH	150
8.4 CHROMOGENIC IN SITU HYBRIDIZATION (CISH)	153
8.4.1 ENHANCED PROBE TECHNOLOGY AND BETTER WORKFLOW AUTOMATION TO BOOST MARKET GROWTH	153
8.5 OTHER TECHNIQUES	157
9 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION	161
9.1 INTRODUCTION	162
9.2 GENETIC DISORDERS	162
9.2.1 EXPANDED CLINICAL GUIDELINES AND IMPROVED CMA/FISH TECHNOLOGIES TO PROPEL MARKET GROWTH	162
9.3 CANCER	166
9.3.1 RISING CANCER RESEARCH AND INCREASING USE OF AUTOMATED CYTOGENETIC PLATFORMS TO DRIVE MARKET	166
9.4 PERSONALIZED MEDICINE	169
9.4.1 STRATEGIC COLLABORATIONS AND BIOMARKER-DRIVEN CYTOGENETIC TESTING TO ACCELERATE MARKET GROWTH	169
9.5 OTHER APPLICATIONS	173
10 MOLECULAR CYTOGENETICS MARKET, BY END USER	177

10.1 INTRODUCTION	178
10.2 CLINICAL & DIAGNOSTIC LABORATORIES	178
10.2.1 INVESTMENT IN AUTOMATION AND INDUSTRY PARTNERSHIPS TO DRIVE MARKET GROWTH	178
10.3 ACADEMIC & RESEARCH INSTITUTES	182
10.3.1 STRATEGIC ACADEMIA-INDUSTRY COLLABORATIONS TO AUGMENT MARKET GROWTH	182
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	185
10.4.1 STRATEGIC ACQUISITIONS AND PRECISION MEDICINE INTEGRATION TO FUEL MARKET GROWTH	185
10.5 OTHER END USERS	189
?	
11 MOLECULAR CYTOGENETICS MARKET, BY REGION	193
11.1 INTRODUCTION	194
11.2 NORTH AMERICA	194
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA	194
11.2.2 US	199
11.2.2.1 US to dominate North American molecular cytogenetics market during study period	199
11.2.3 CANADA	202
11.2.3.1 Increasing cancer burden and expanding application of cytogenetics technology in oncology to drive market	202
11.3 EUROPE	205
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE	205
11.3.2 GERMANY	210
11.3.2.1 Dynamic convergence of research excellence, clinical adoption, and industry collaboration to augment market growth	210
11.3.3 UK	213
11.3.3.1 Strong governmental support for genomics research and advanced healthcare infrastructure to aid market growth	213
11.3.4 FRANCE	215
11.3.4.1 Increasing government investment in pharmaceutical industry to support market growth	215
11.3.5 ITALY	218
11.3.5.1 Rising research activities in pharma R&D to boost market growth	218
11.3.6 SPAIN	221
11.3.6.1 Well-established network of research centers and universities to boost clinical and diagnostic research	221
11.3.7 REST OF EUROPE	224
11.4 ASIA PACIFIC	227
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	227
11.4.2 CHINA	232
11.4.2.1 Development of advanced healthcare infrastructure and government support for genomics research to propel growth	232
11.4.3 JAPAN	235
11.4.3.1 Technological adoption and increased clinical programs to favor market growth	235
11.4.4 INDIA	238
11.4.4.1 Rising awareness of cancer and genetic disorders to support market growth	238
11.4.5 AUSTRALIA	241
11.4.5.1 Progressive translational research, advanced diagnostic integration, and cross-institutional collaborations to fuel growth	241
11.4.6 SOUTH KOREA	244
11.4.6.1 Technological innovation and high demand for precision medicines to aid market growth	244
11.4.7 REST OF ASIA PACIFIC	247
11.5 LATIN AMERICA	250
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA	250
11.5.2 BRAZIL	254

11.5.2.1	Increased number of public-private collaborations to focus on strategic market expansions	254
11.5.3	MEXICO	257
11.5.3.1	Strengthening genomic infrastructure and technology integration to support market growth	257
11.5.4	REST OF LATIN AMERICA	260
11.6	MIDDLE EAST	263
11.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	263
11.6.2	GCC COUNTRIES	267
11.6.2.1	Kingdom of Saudi Arabia	270
11.6.2.1.1	Growing healthcare expenditure to boost market growth	270
11.6.2.2	UAE	273
11.6.2.2.1	Rising government support and incorporation of ISH technologies by hospitals to aid market growth	273
11.6.2.3	Rest of GCC countries	276
11.6.3	REST OF MIDDLE EAST	279
11.7	AFRICA	282
11.7.1	GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR GENETIC TESTING TO PROPEL GROWTH	282
11.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	282
12	COMPETITIVE LANDSCAPE	286
12.1	INTRODUCTION	286
12.2	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS	286
12.3	REVENUE ANALYSIS, 2020-2024	289
12.4	MARKET SHARE ANALYSIS, 2024	290
12.5	COMPANY VALUATION & FINANCIAL METRICS	292
12.5.1	FINANCIAL METRICS	292
12.5.2	COMPANY VALUATION	292
12.6	BRAND/PRODUCT COMPARISON	293
12.6.1	F. HOFFMANN-LA ROCHE LTD.	293
12.6.2	DANAHER CORPORATION	294
12.6.3	AGILENT TECHNOLOGIES, INC.	294
12.6.4	ABBOTT	294
12.6.5	THERMO FISHER SCIENTIFIC INC.	294
12.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	294
12.7.1	STARS	294
12.7.2	EMERGING LEADERS	294
12.7.3	PERVASIVE PLAYERS	295
12.7.4	PARTICIPANTS	295
12.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	296
12.7.5.1	Company footprint	296
12.7.5.2	Region footprint	296
12.7.5.3	Product & service footprint	297
12.7.5.4	Technique footprint	298
12.7.5.5	Application footprint	298
12.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	299
12.8.1	PROGRESSIVE COMPANIES	299
12.8.2	RESPONSIVE COMPANIES	299
12.8.3	DYNAMIC COMPANIES	299
12.8.4	STARTING BLOCKS	299
12.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	301

12.8.5.1	Detailed list of key startups/SMEs	301
12.8.5.2	Competitive benchmarking of key startups/SMEs	302
12.9	COMPETITIVE SCENARIO	303
12.9.1	PRODUCT LAUNCHES & APPROVALS	303
12.9.2	DEALS	304
12.9.3	EXPANSIONS	305
12.9.4	OTHER DEVELOPMENTS	305
13	COMPANY PROFILES	306
13.1	KEY PLAYERS	306
13.1.1	F. HOFFMANN-LA ROCHE LTD.	306
13.1.1.1	Business overview	306
13.1.1.2	Products/Services offered	307
13.1.1.3	Recent developments	309
13.1.1.3.1	Product launches & approvals	309
13.1.1.4	MnM view	310
13.1.1.4.1	Key strengths	310
13.1.1.4.2	Strategic choices	310
13.1.1.4.3	Weaknesses & competitive threats	310
13.1.2	DANAHER CORPORATION	311
13.1.2.1	Business overview	311
13.1.2.2	Products/Services offered	312
13.1.2.3	Recent developments	314
13.1.2.3.1	Product launches	314
13.1.2.3.2	Deals	315
13.1.2.4	MnM view	315
13.1.2.4.1	Key strengths	315
13.1.2.4.2	Strategic choices	315
13.1.2.4.3	Weaknesses & competitive threats	316
?		
13.1.3	AGILENT TECHNOLOGIES, INC.	317
13.1.3.1	Business overview	317
13.1.3.2	Products/Services offered	318
13.1.3.3	Recent developments	320
13.1.3.3.1	Product launches	320
13.1.3.3.2	Deals	321
13.1.3.3.3	Other developments	321
13.1.3.4	MnM view	322
13.1.3.4.1	Key strengths	322
13.1.3.4.2	Strategic choices	322
13.1.3.4.3	Weaknesses & competitive threats	322
13.1.4	ABBOTT	323
13.1.4.1	Business overview	323
13.1.4.2	Products/Services offered	324
13.1.4.3	MnM view	325
13.1.4.3.1	Key strengths	325
13.1.4.3.2	Strategic choices	325
13.1.4.3.3	Weaknesses & competitive threats	325

- 13.1.5.0 THERMO FISHER SCIENTIFIC INC. 326
- 13.1.5.1 Business overview 326
- 13.1.5.2 Products/Services offered 327
- 13.1.5.3 Recent developments 329
- 13.1.5.3.1 Product launches 329
- 13.1.5.3.2 Deals 329
- 13.1.5.4 MnM view 330
- 13.1.5.4.1 Key strengths 330
- 13.1.5.4.2 Strategic choices 330
- 13.1.5.4.3 Weaknesses & competitive threats 330
- 13.1.6 ILLUMINA, INC. 331
- 13.1.6.1 Business overview 331
- 13.1.6.2 Products/Services offered 332
- 13.1.6.3 Recent developments 333
- 13.1.6.3.1 Deals 333
- 13.1.6.3.2 Expansions 334
- 13.1.7 REVVITY 335
- 13.1.7.1 Business overview 335
- 13.1.7.2 Products/Services offered 336
- 13.1.7.3 Recent developments 337
- 13.1.7.3.1 Product launches 337
- 13.1.7.3.2 Deals 338
- ?
- 13.1.8 PACBIO 339
- 13.1.8.1 Business overview 339
- 13.1.8.2 Products/Services offered 340
- 13.1.8.3 Recent developments 341
- 13.1.8.3.1 Deals 341
- 13.1.8.3.2 Expansions 342
- 13.1.9 BIO-RAD LABORATORIES, INC. 343
- 13.1.9.1 Business overview 343
- 13.1.9.2 Products/Services offered 344
- 13.1.10 BIO-TECHNE 347
- 13.1.10.1 Business overview 347
- 13.1.10.2 Products/Services offered 348
- 13.1.10.3 Recent developments 349
- 13.1.10.3.1 Product launches 349
- 13.1.10.3.2 Deals 350
- 13.1.11 GENE DX, LLC 351
- 13.1.11.1 Business overview 351
- 13.1.11.2 Products/Services offered 352
- 13.1.11.3 Recent developments 352
- 13.1.11.3.1 Deals 352
- 13.1.12 INSIGHT MOLECULAR DIAGNOSTICS INC. 353
- 13.1.12.1 Business overview 353
- 13.1.12.2 Products/Services offered 354
- 13.1.13 BIOVIEW 355

13.1.13.1 Business overview	355
13.1.13.2 Products/Services offered	355
13.2 OTHER PLAYERS	357
13.2.1 OXFORD GENE TECHNOLOGY IP LIMITED	357
13.2.2 APPLIED SPECTRAL IMAGING	358
13.2.3 CYTOTEST INC.	359
13.2.4 KROMATID	360
13.2.5 GENIAL GENETIC SOLUTIONS LTD.	361
13.2.6 CYTOGNOMIX INC.	362
13.2.7 METASYSTEMS	363
13.2.8 SCIGENE CORPORATION	364
13.2.9 BIOMODAL	365
13.2.10 BIOCARE MEDICAL, LLC	366
13.2.11 BIODOT	367
13.2.12 ONCODNA	368
?	
14 APPENDIX	369
14.1 DISCUSSION GUIDE	369
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	373
14.3 CUSTOMIZATION OPTIONS	375
14.4 RELATED REPORTS	375
14.5 AUTHOR DETAILS	376

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

**Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030**

Market Report | 2025-10-14 | 377 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>	EU Vat / Tax ID / NIP number*	
Company Name*	<input type="text"/>	<input type="text"/>	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

Zip Code\*

Country\*

Date

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)